PTC Therapeutics, Inc. Common Stock PTCT
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-12T02:45:09.869Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T21:11:54.583702744Z
FundamentalsAlpha Vantage · ready · quarter 2026-09-30 · fetched 2026-11-12T02:45:09.402286+00:00
PTC Therapeutics, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 75.79 | 108.4% | 18.8% | 57.10 | 103.5% | 13.7% |
| 25Δ | 71.94 | 87.1% | 13.0% | 60.03 | 80.3% | 9.2% |
| 30Δ | 69.50 | 72.6% | 9.3% | 60.99 | 72.5% | 7.9% |
| 35Δ | 68.34 | 64.8% | 7.7% | 61.96 | 64.6% | 6.5% |
| 40Δ | 67.18 | 57.0% | 6.0% | 62.92 | 56.8% | 5.1% |
| 45Δ | 66.03 | 49.3% | 4.4% | 63.89 | 48.9% | 3.8% |
| 50Δ | 64.91 | 42.7% | 2.9% | 64.86 | 41.1% | 2.4% |
| 55Δ | 64.12 | 45.3% | 2.6% | 65.53 | 39.5% | 2.0% |
| 60Δ | 63.32 | 48.0% | 2.3% | 66.15 | 39.0% | 1.7% |
| 65Δ | 62.53 | 50.6% | 2.0% | 66.77 | 38.5% | 1.5% |
| 70Δ | 61.73 | 53.3% | 1.7% | 67.39 | 38.0% | 1.2% |
| 75Δ | 60.94 | 56.0% | 1.4% | 68.01 | 37.5% | 1.0% |
| 80Δ | 60.14 | 58.6% | 1.2% | 68.63 | 37.0% | 0.7% |
20Δ
- Pseudo strike
- 75.79
- IV
- 108.4%
- B/E move
- 18.8%
- Pseudo strike
- 57.10
- IV
- 103.5%
- B/E move
- 13.7%
25Δ
- Pseudo strike
- 71.94
- IV
- 87.1%
- B/E move
- 13.0%
- Pseudo strike
- 60.03
- IV
- 80.3%
- B/E move
- 9.2%
30Δ
- Pseudo strike
- 69.50
- IV
- 72.6%
- B/E move
- 9.3%
- Pseudo strike
- 60.99
- IV
- 72.5%
- B/E move
- 7.9%
35Δ
- Pseudo strike
- 68.34
- IV
- 64.8%
- B/E move
- 7.7%
- Pseudo strike
- 61.96
- IV
- 64.6%
- B/E move
- 6.5%
40Δ
- Pseudo strike
- 67.18
- IV
- 57.0%
- B/E move
- 6.0%
- Pseudo strike
- 62.92
- IV
- 56.8%
- B/E move
- 5.1%
45Δ
- Pseudo strike
- 66.03
- IV
- 49.3%
- B/E move
- 4.4%
- Pseudo strike
- 63.89
- IV
- 48.9%
- B/E move
- 3.8%
50Δ
- Pseudo strike
- 64.91
- IV
- 42.7%
- B/E move
- 2.9%
- Pseudo strike
- 64.86
- IV
- 41.1%
- B/E move
- 2.4%
55Δ
- Pseudo strike
- 64.12
- IV
- 45.3%
- B/E move
- 2.6%
- Pseudo strike
- 65.53
- IV
- 39.5%
- B/E move
- 2.0%
60Δ
- Pseudo strike
- 63.32
- IV
- 48.0%
- B/E move
- 2.3%
- Pseudo strike
- 66.15
- IV
- 39.0%
- B/E move
- 1.7%
65Δ
- Pseudo strike
- 62.53
- IV
- 50.6%
- B/E move
- 2.0%
- Pseudo strike
- 66.77
- IV
- 38.5%
- B/E move
- 1.5%
70Δ
- Pseudo strike
- 61.73
- IV
- 53.3%
- B/E move
- 1.7%
- Pseudo strike
- 67.39
- IV
- 38.0%
- B/E move
- 1.2%
75Δ
- Pseudo strike
- 60.94
- IV
- 56.0%
- B/E move
- 1.4%
- Pseudo strike
- 68.01
- IV
- 37.5%
- B/E move
- 1.0%
80Δ
- Pseudo strike
- 60.14
- IV
- 58.6%
- B/E move
- 1.2%
- Pseudo strike
- 68.63
- IV
- 37.0%
- B/E move
- 0.7%
Options history
Table
| Date | IV (%) |
|---|---|
| 57.21% | |
| 55.77% | |
| 56.35% | |
| 58.40% | |
| 61.02% | |
| 62.35% | |
| 61.94% | |
| 61.52% | |
| 61.37% | |
| 51.09% |
Biotechnology
PTGX
Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical needs. The company is…
More →PVLA
Palvella Therapeutics, Inc. is an innovative biotechnology firm dedicated to developing transformative therapies for rare genetic disorders resulting from specific gene mutations.…
More →PYPD
PolyPid Ltd., an advanced stage biopharmaceutical company, develops, manufactures and markets products based on the Polymer Lipid Encapsulation Matrix (PLEX) platform to address…
More →PYXS
Pyxis Oncology, Inc., a preclinical biotechnology company, is dedicated to developing antibody-drug conjugate (ADC) and monoclonal antibody (mAb) immunotherapies for treating…
More →QTTB
Q32 Bio Inc. (QTTB) is a pioneering biotechnology firm focused on the development of advanced antibody-based therapies for autoimmune diseases and immune response optimization.…
More →QURE
Description unavailable
More →